Table 1. Clinical trials targeting the ovarian cancer cells and their interactions with tumor microenvironment.
| Drug | Target | Clinical Trial | NCT Trial |
|---|---|---|---|
| Aflibercept (VEGF trap) | vascular endothelial growth factor (VEGF) | Phase 2 |
NCT00327171 NCT00327444 NCT00396591 |
| Bevacizumab + paclitaxel and carboplatin | VEGF-A | Phase 3 | NCT01239732 |
| Bevacizumab and Erlotinib | VEGF-A + EGFR | Phase 2 | NCT00130520 |
| Bevacizumab + Carboplatin | VEGF-A | Phase 2 |
NCT00937560 NCT00744718 |
| Chiauranib | serine-threonine kinases: aurora kinase B (aurora B), VEGF receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs) | Phase 1 Phase 2 | NCT03166891 |
| Nintedanib + Bevacizumab | VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β (angiogenesis and fibrosis) | Phase 1 | NCT02835833 |
| INCB062079 | fibroblast growth factor receptor 4 (FGFR4) | Phase 1 | NCT03144661 |
| Sorafinib + paclitaxel and carboplatin | Multi-targeted Receptor Tyrosine Kinase Inhibitor (RTKi) | Phase 2 | NCT00390611 |
| Sunitinib (SU11248) | Multi-targeted RTKi | Phase 2 | NCT00543049 NCT00768144 NCT00453310 |
| Tocilizumab and Interferon alpha 2-b (IFN-α2b)+ Carboplatin and Caelyx or doxorubicin | Interleukin-6 receptor (IL-6R) | Phase 1 | NCT01637532 |
| Siltuximab (CNTO 328) | IL-6R | Phase 2 | NCT00841191 |
| Plerixafor | CXCR4 | Phase 1 |
NCT02179970 NCT03277209 |
| PD 0360324+ cyclophosphamide | Macrophage colony stimulating factor (M-CSF) | Phase 2 | NCT02948101 |
| Celecoxib + cyclophosphamide | cyclooxygenases (COX-1 and COX-2) | Phase 2 | NCT00538031 |
| Ketorolac | COX-1 and COX-2/GTPase inhibition | Phase 0 | NCT02470299 |
| Metformin + paclitaxel and carboplatin | Antidiabetic medication/metabolism | Phase 1 Phase 2 | NCT02312661 NCT02437812 |
| Metformin | Antidiabetic medication/metabolism | Phase 2 | NCT01579812 |
| Metformin+ atorvastatin + doxycycline+ mebendazole | Antidiabetic medication/metabolism (glucose and lipid levels) | Phase 3 | NCT02201381 |
| INCAGN01876 + Nivolumab + Ipilimumab | Tumor necrosis factor α (TNFα), Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocytes’ CTLA-4. | Phase 1 Phase 2 | NCT03126110 |
| MK-3475 (pembrolizumab) + Gemcitabine and cisplatin | PD-1 | Phase 2 | NCT02608684 |
| Oregovomab and Nivolumab | Cancer Antigen 125 (CA-125) and PD-1 | Phase 1 Phase 2 | NCT03100006 |
| Durvalumab (MEDI4736 + motolimod) + pegylated liposomal doxorubicin | Programmed cell death ligand 1(PD-L1) and Toll like receptor 8 (TLL8) | Phase1 Phase 2 | NCT02431559 |
| Autologous Monocytes + Sylatron (PegIFNα)+ Actimmune (IFNγ-1b) | Immunotherapy | Phase 1 | NCT02948426 |
| Vigil bi-shRNA furin and GMCSF (FANG) Augmented Autologous Tumor Cell Immunotherapy | TGFβ1 and TGFβ2 (tumor)+ Immune stimulation | Phase 2 | NCT02346747 |
| Vigil (Adjuvant FANG) | TGFβ1 and TGFβ2 (tumor) + Immune stimulation | Phase 2 | NCT01309230 |
| Atezolizumab and Vigil | PDL1 and TGFβ1 and TGFβ2 (tumor) | Phase 2 | NCT03073525 |
| NK immunotherapy | Combination of Cryosurgery and NK Immunotherapy | Phase 2 | NCT02849353 |
| Therapeutic autologous Antigen-Specific CD4+ lymphocytes | Immunotherapy | Phase 1 | NCT00101257 |